Glycogen synthase kinase‐3 inhibitors suppress the AR‐V7‐mediated transcription and selectively inhibit cell growth in AR‐V7‐positive prostate cancer cells
1. Oncology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan;2. Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan